U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07542314) titled 'Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting' on April 02.

Brief Summary: The primary objective of this study is to evaluate acute liver injury (ALI) rates associated with ELEVIDYS with the addition of sirolimus as an adjunct prophylactic immunosuppression agent.

Study Start Date: April 30

Study Type: INTERVENTIONAL

Condition: Duchenne Muscular Dystrophy

Intervention: DRUG: ELEVIDYS

Administered via an intravenous infusion.

DRUG: Sirolimus

Administered orally.

DRUG: Glucocorticoids

Administered orally.

DRUG: Antibiotics

A...